APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing Today

Aprea Therapeutics (NASDAQ:APRE) stock is seeing major gains on Wednesday after revealing results from a recent Phase 1/2 trial for eprenetapopt, venetoclax, and azacitidine.

colorful pills and vials sitting on a table
Source: Bukhta Yurii / Shutterstock.com

The company was using eprenetapopt, venetoclax, and azacitidine to treat patients suffering from TP53 mutant AML. This saw the treatment meet its primary efficacy endpoint of complete remission rate.

This saw the 30 patients in the study receiving the treatment achieving a complete remission rate of 37%.composite response rate of CR plus CR with incomplete hematologic recovery of 53%. 11 patients continue to remain on treatment to evaluate safety and efficacy.

Eyal Attar, M.D., CMO of Aprea Therapeutics, said this about the news that’s sending APRE stock soaring today.

“We are pleased with these results from the combination of eprenetapopt with venetoclax and azacitidine in this very difficult-to-treat TP53 mutant AML population, a patient group with significant unmet medical need. These data, which follow the recent granting of Fast Track and Orphan Drug designations by FDA, provide further demonstration of the potential for eprenetapopt in the treatment of myeloid malignancies.”

Aprea Therapeutics notes that it plans to present data from the study to the U.S. Food and Drug Administration (FDA) in the second half of the year. It also says that it will provide additional information from the study in a future scientific or medical conference.

APRE stock is seeing heavy trading following the study results. As of this writing, more than 120 million shares of the stock have changed hands. That’s a massive jump compared to its daily average trading volume of 740,000 shares.

APRE stock was up 24.7% as of noon Wednesday.

Investors that are looking for more hot stocks to keep track of this morning should keep reading.

There’s plenty of stock market news to discuss today with many companies seeing major movement for their shares. That includes the latest concerning Greenland Technologies (NASDAQ:GTEC), WalkMe (NASDAQ:WKME), and SPI Energy (NASDAQ:SPI). You can learn all about these subjects in the links below.

More Stock Market News for Wednesday

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed


Article printed from InvestorPlace Media, https://investorplace.com/2021/06/apre-stock-the-big-leukemia-study-news-that-has-aprea-therapeutics-skyrocketing-today/.

©2021 InvestorPlace Media, LLC